{"id":"NCT01699685","sponsor":"Novartis Pharmaceuticals","briefTitle":"Swiss studY for the Treatment of COPD Patients With the Free combiNation of indacatERol and GlYcopyrroniumbromide.","officialTitle":"A Multicenter, Randomized, Double-blind, Single-dose Study to Assess the Effect of the QAB149 and NVA237 Combination Versus QAB149 Alone on Inspiratory Capacity in Patients With Moderate or Severe COPD.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-11","primaryCompletion":"2014-06","completion":"2014-06","firstPosted":"2012-10-04","resultsPosted":"2016-02-09","lastUpdate":"2016-02-09"},"enrollment":79,"design":{"allocation":"RANDOMIZED","model":"CROSSOVER","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Chronic Obstructive Pulmonary Disease: COPD"],"interventions":[{"type":"DRUG","name":"QAB149","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"NVA237","otherNames":[]}],"arms":[{"label":"Sequence A","type":"PLACEBO_COMPARATOR"},{"label":"Sequence B","type":"ACTIVE_COMPARATOR"}],"summary":"The study purpose is to evaluate the effect of QAB149\n\n* NVA237 vs. QAB149 on static lung hyperinflation.","primaryOutcome":{"measure":"Inspiratory Capacity (IC) Peak Value","timeFrame":"Day (0) 30minutes, 1, 2, 3, and 4 hours; Day (6) 30 minutes, 1, 2, 3, and 4 hours","effectByArm":[{"arm":"Sequence A","deltaMin":2.87,"sd":0.808},{"arm":"Sequence B","deltaMin":2.94,"sd":0.777}],"pValues":[]},"eligibility":{"minAge":"40 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":5},"locations":{"siteCount":11,"countries":["Switzerland"]},"refs":{"pmids":["28077140"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":39},"commonTop":["Forced expiratory volume decreased","Chronic obstructive pulmonary disease","Nasopharyngitis","Inspiratory capacity decreased","Arthralgia"]}}